Intent-to-treat median PFS was 10.2 months with nivolumab/ipilimumab versus 6.3 months with added SBRT, with 12-month PFS 47.8% versus 34.9% (HR 1.20; P=.56). Per-protocol analysis after four ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...

In the absence of trials, a post hoc analysis compared stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy (HDR-BT) in intermediate-risk prostate cancer.

Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim ...

Treatment with five-fraction SBRT for prostate cancer may be more convenient than receiving traditional radiation therapy techniques, an expert said. For patients with low- to intermediate-risk ...

Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer ...

The use of magnetic resonance–guided daily adaptive stereotactic body radiotherapy (SBRT) for patients with prostate cancer reduces the risk of acute urinary side effects of grade 2 or higher by 44% ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...